Showing results (61-70 of 71) with videos related to

Sort By:
Pageof 8
Blood Advances|July 30, 2025
Real-World Outcomes of Infections Following Tisagenlecleucel in Patients with B-Cell ALL: A CIBMTR AnalysisHemalatha G Rangarajan, Prakash Satwani, Megan M Herr, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Blood|March 17, 2018
MAGIC biomarkers predict long-term outcomes for steroid-resistant acute GVHDHannah Major-Monfried, Anne S Renteria, Attaphol Pawarode, et al.
Transplantation and Cellular Therapy|February 6, 2024
A Day 14 Endpoint for Acute GVHD Clinical TrialsNikolaos Spyrou, Yu Akahoshi, Steven Kowalyk, et al.
Transplantation and Cellular Therapy|June 24, 2026
Comparison of Fludarabine Versus Bendamustine as a Lymphodepleting Chemotherapy Prior to CAR-T for Large Cell LymphomaNausheen Ahmed, Alaa Ali, Soyoung Kim, et al.
Blood Advances|December 10, 2019
The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host diseaseHrishikesh K Srinagesh, Umut Özbek, Urvi Kapoor, et al.
Transplantation and Cellular Therapy|April 27, 2025
Cytokine Release Syndrome and Neurotoxicity Following CD19 CAR-T in B-Cell LymphomaRoni Shouval, Christopher Strouse, Soyoung Kim, et al.
Blood Advances|May 28, 2025
Infection after CD19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: real-world analysis from CIBMTRKitsada Wudhikarn, Megan M Herr, Min Chen, et al.
Blood Neoplasia|March 23, 2026
Impact of age on outcomes after CD19 CAR T-cell therapy for large B-cell lymphomasAbu-Sayeef Mirza, Chitra Hosing, Francine Foss, et al.
Blood Advances|August 14, 2025
New Comorbidity Index Associated with Survival After Chimeric Antigen Receptor T Cell Therapy for Large B-Cell LymphomaUri Greenbaum, Hamza Hashmi, Mahmoud Elsawy, et al.
Pageof 8